EQUITY	12 Months Ended
Jun. 30, 2019
EQUITY
EQUITY	(10) EQUITY On May 7, 2018, our Board of Directors authorized the repurchase of up to $500 million of our common stock from time to time using a variety of methods, including open market purchases, privately negotiated transactions and other means in accordance with federal securities laws. During the year ended June 30, 2019, the Company repurchased 12,973,892 shares of its outstanding common stock at an average price of $31.03, or $402.5 million. During the year ended June 30, 2018, the Company repurchased 2,749,079 shares of its outstanding common stock at an average price of $34.02, or $93.5 million. The authorization expired on November 7, 2018 with the Company having repurchased $496.0 million under the authorization. During the years ended June 30, 2019 and June 30, 2018, the Company recorded increases of $102.1 million and $91.1 million respectively, in additional paid-in capital associated with stock-based compensation expense related to the Company’s equity classified stock-based compensation awards. See Note 11 –Stock-based Compensation.

EQUITY

12 Months Ended

Jun. 30, 2019

(10) EQUITY

On May 7, 2018, our Board of Directors authorized the repurchase of up to $500 million of our common stock from time to time using a variety of methods, including open market purchases, privately negotiated transactions and other means in accordance with federal securities laws. During the year ended June 30, 2019, the Company repurchased 12,973,892 shares of its outstanding common stock at an average price of $31.03, or $402.5 million. During the year ended June 30, 2018, the Company repurchased 2,749,079 shares of its outstanding common stock at an average price of $34.02, or $93.5 million. The authorization expired on November 7, 2018 with the Company having repurchased $496.0 million under the authorization.

During the years ended June 30, 2019 and June 30, 2018, the Company recorded increases of $102.1 million and $91.1 million respectively, in additional paid-in capital associated with stock-based compensation expense related to the Company’s equity classified stock-based compensation awards. See Note 11 –Stock-based Compensation.